Lupin launches generic Fenofibric Acid capsules in US market

Drug firm Lupin today said its US arm has launched generic Fenofibric Acid capsules


used for reducing cholesterol and fatty acids in the blood in the American market.

Lupin Pharmaceuticals Inc (LPI), the company's US subsidiary has launched its generic Fenofibric Acid Delayed- release capsules in the strengths of 45 mg and 135 mg, Lupin Ltd said in a statement.

The company had earlier received the final approval from the US health regulator (USFDA) for the same, it added.

The company's generic products are generic equivalent of AbbVie Inc's Trilipix delayed-release capsules in the same strengths.

As per the IMS MAT September 2013 data, Trilipix delayed- release capsules in the strengths of 45 mg and 135 mg had annual US sales of nearly $449.5 million, Lupin said.

"The capsules are indicated as co-administration therapy with statins for the treatment of mixed dyslipidemia,treatment of severe hypertriglyceridemia and primary hyperchol esterolemia or mixed dyslipidemia," it added.

Shares of Lupin Ltd were today trading at Rs 859 per scrip on BSE, up 0.42% from its previous close.

Post new comment

E-mail ID will not be published
This question is for testing whether you are a human visitor and to prevent automated spam submissions.


  • The economic survey falls in step with the BJP’s election manifesto

    It’s always tough to find something wrong with the annual economic survey as it only articulates the government’s desire to set its house in order


Stay informed on our latest news!


GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India


Arun Nigavekar

Why higher education needs innovation

India is such a great country that it creates complexity ...

Zehra Naqvi

We must overcome the fear of death

It is the biggest irony that the only thing that’s ...

Dharmendra Khandal

Jawai leopards and locals can coexist peacefully

At first glance, the Jawai landscape seems like a large ...


William D. Green

Chairman & CEO, Accenture